{
    "title": "Medicare Home Infusion Therapy Access Act of 2017",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medicare Home Infusion Therapy \nAccess Act of 2017''.\n\nSEC. 2. HOME INFUSION THERAPY SERVICES TEMPORARY TRANSITIONAL PAYMENT.\n\n    (a) In General.--Section 1834(u) of the Social Security Act (42 \nU.S.C. 1395m(u)) is amended, by adding at the end the following new \nparagraph:\n            ``(7) Home infusion therapy services temporary transitional \n        payment.--\n                    ``(A) Temporary transitional payment.--\n                            ``(i) In general.--The Secretary shall, in \n                        accordance with the payment methodology \n                        described in subparagraph (B) and subject to \n                        the provisions of this paragraph, provide a \n                        home infusion therapy services temporary \n                        transitional payment under this part to an \n                        eligible home infusion supplier (as defined in \n                        subparagraph (F)) for items and services \n                        described in subparagraphs (A) and (B) of \n                        section 1861(iii)(2) furnished during the \n                        period specified in clause (ii) by such \n                        supplier in coordination with the furnishing of \n                        transitional home infusion drugs (as defined in \n                        clause (iii)).\n                            ``(ii) Period specified.--For purposes of \n                        clause (i), the period specified in this clause \n                        is the period beginning on January 1, 2019, and \n                        ending on the day before the date of the \n                        implementation of the payment system under \n                        paragraph (1)(A).\n                            ``(iii) Transitional home infusion drug \n                        defined.--For purposes of this paragraph, the \n                        term `transitional home infusion drug' has the \n                        meaning given to the term `home infusion drug' \n                        under section 1861(iii)(3)(C), except that \n                        clause (ii) of such section shall not apply if \n                        a drug described in such clause is identified \n                        in clause (i), (ii), (iii) or (iv) of \n                        subparagraph (C) as of the date of the \n                        enactment of this paragraph.\n                    ``(B) Payment methodology.--For purposes of this \n                paragraph, the Secretary shall establish a payment \n                methodology, with respect to items and services \n                described in subparagraph (A)(i). Under such payment \n                methodology the Secretary shall--\n                            ``(i) create the three payment categories \n                        described in clauses (i), (ii), and (iii) of \n                        subparagraph (C);\n                            ``(ii) assign drugs to such categories, in \n                        accordance with such clauses;\n                            ``(iii) assign appropriate Healthcare \n                        Common Procedure Coding System (HCPCS) codes to \n                        each payment category; and\n                            ``(iv) establish a single payment amount \n                        for each such payment category, in accordance \n                        with subparagraph (D), for each infusion drug \n                        administration calendar day in the individual's \n                        home for drugs assigned to such category.\n                    ``(C) Payment categories.--\n                            ``(i) Payment category 1.--The Secretary \n                        shall create a payment category 1 and assign to \n                        such category drugs which are covered under the \n                        Local Coverage Determination on External \n                        Infusion Pumps (LCD number L33794) and billed \n                        with the following HCPCS codes (as identified \n                        as of July 1, 2017, and as subsequently \n                        modified by the Secretary): J0133, J0285, \n                        J0287, J0288, J0289, J0895, J1170, J1250, \n                        J1265, J1325, J1455, J1457, J1570, J2175, \n                        J2260, J2270, J2274, J2278, J3010, or J3285.\n                            ``(ii) Payment category 2.--The Secretary \n                        shall create a payment category 2 and assign to \n                        such category drugs which are covered under \n                        such local coverage determination and billed \n                        with the following HCPCS codes (as identified \n                        as of July 1, 2017, and as subsequently \n                        modified by the Secretary): J1559 JB, J1561 JB, \n                        J1562 JB, J1569 JB, or J1575 JB.\n                            ``(iii) Payment category 3.--The Secretary \n                        shall create a payment category 3 and assign to \n                        such category drugs which are covered under \n                        such local coverage determination and billed \n                        with the following HCPCS codes (as identified \n                        as of July 1, 2017, and as subsequently \n                        modified by the Secretary): J9000, J9039, \n                        J9040, J9065, J9100, J9190, J9200, J9360, or \n                        J9370.\n                            ``(iv) Infusion drugs not otherwise \n                        included.--With respect to drugs that are not \n                        included in payment category 1, 2, or 3 under \n                        clause (i), (ii), or (iii), respectively, the \n                        Secretary shall assign to the most appropriate \n                        of such categories, as determined by the \n                        Secretary, drugs which are--\n                                    ``(I) covered under such local \n                                coverage determination and billed under \n                                HCPCS code J7799 or J7999 (as \n                                identified as of July 1, 2017, and as \n                                subsequently modified by the \n                                Secretary); or\n                                    ``(II) billed under any code that \n                                is implemented after the date of the \n                                enactment of this paragraph and \n                                included in such local coverage \n                                determination or included in \n                                subregulatory guidance as a home \n                                infusion drug described in subparagraph \n                                (A)(i).\n                    ``(D) Payment amounts.--\n                            ``(i) In general.--Under the payment \n                        methodology, the Secretary shall pay eligible \n                        home infusion suppliers, with respect to items \n                        and services described in subparagraph (A)(i) \n                        furnished during the period described in \n                        subparagraph (A)(ii) by such supplier to an \n                        individual, at amounts equal to the amounts \n                        determined under the physician fee schedule \n                        established under section 1848 for services \n                        furnished during the year for codes and units \n                        of such codes described in clauses (ii), (iii), \n                        and (iv) with respect to drugs included in the \n                        payment category under subparagraph (C) \n                        specified in the respective clause, determined \n                        without application of any adjustment under \n                        such section.\n                            ``(ii) Payment amount for category 1.--For \n                        purposes of clause (i), the codes and units \n                        described in this clause, with respect to drugs \n                        included in payment category 1 described in \n                        subparagraph (C)(i), are one unit of HCPCS code \n                        96365 plus four units of HCPCS code 96366 (as \n                        identified as of July 1, 2017, and as \n                        subsequently modified by the Secretary).\n                            ``(iii) Payment amount for category 2.--For \n                        purposes of clause (i), the codes and units \n                        described in this clause, with respect to drugs \n                        included in payment category 2 described in \n                        subparagraph (C)(i), are one unit of HCPCS code \n                        96369 plus four units of HCPCS code 96370 (as \n                        identified as of July 1, 2017, and as \n                        subsequently modified by the Secretary).\n                            ``(iv) Payment amount for category 3.--For \n                        purposes of clause (i), the codes and units \n                        described in this clause, with respect to drugs \n                        included in payment category 3 described in \n                        subparagraph (C)(i), are one unit of HCPCS code \n                        96413 plus four units of HCPCS code 96415 (as \n                        identified as of July 1, 2017, and as \n                        subsequently modified by the Secretary).\n                    ``(E) Clarifications.--\n                            ``(i) Infusion drug administration day.--\n                        For purposes of this subsection, a reference, \n                        with respect to the furnishing of transitional \n                        home infusion drugs or home infusion drugs to \n                        an individual by an eligible home infusion \n                        supplier, to payment to such supplier for an \n                        infusion drug administration calendar day in \n                        the individual's home shall refer to payment \n                        only for the date on which professional \n                        services (as described in section \n                        1861(iii)(2)(A)) were furnished to administer \n                        such drugs to such individual. For purposes of \n                        the previous sentence, an infusion drug \n                        administration calendar day shall include all \n                        such drugs administered to such individual on \n                        such day.\n                            ``(ii) Treatment of multiple drugs \n                        administered on same infusion drug \n                        administration day.--In the case that an \n                        eligible home infusion supplier, with respect \n                        to an infusion drug administration calendar day \n                        in an individual's home, furnishes to such \n                        individual transitional home infusion drugs \n                        which are not all assigned to the same payment \n                        category under subparagraph (C), payment to \n                        such supplier for such infusion drug \n                        administration calendar day in the individual's \n                        home shall be a single payment equal to the \n                        amount of payment under this paragraph for the \n                        drug, among all such drugs so furnished to such \n                        individual during such calendar day, for which \n                        the highest payment would be made under this \n                        paragraph.\n                    ``(F) Eligible home infusion suppliers.--In this \n                paragraph, the term `eligible home infusion supplier' \n                means a supplier that is enrolled under this part as a \n                pharmacy that provides external infusion pumps and \n                external infusion pump supplies and that maintains all \n                pharmacy licensure requirements in the State in which \n                the applicable infusion drugs are administered.\n                    ``(G) Implementation.--Notwithstanding any other \n                provision of law, the Secretary may implement this \n                paragraph by program instruction or otherwise.''.\n    (b) Conforming Amendment.--Section 1842(b)(6)(I) of the Social \nSecurity Act (42 U.S.C. 1395u(b)(6)(I)) is amended by inserting ``or, \nin the case of items and services described in clause (i) of section \n1834(u)(7)(A) furnished to an individual during the period described in \nclause (ii) of such section, payment shall be made to the eligible home \ninfusion therapy supplier'' after ``payment shall be made to the \nqualified home infusion therapy supplier''."
}